Global CNS Specific Antisense Oligonucleotides Market Size, Status and Forecast 2022

Antisense oligonucleotides are single-stranded oligodeoxynucleotides that can alter the RNA and modify protein expression. These oligonucleotides were discovered to influence RNA processing. Subsequent chemical modifications of antisense oligonucleotides were used to address issues such as off-target toxic effects and insufficient biological activity. These modifications led to an improved mechanism of antisense oligonucleotides and clinical trial design. This paved the way toward translating their use into therapies for various genetic and neurological conditions. Antisense oligonucleotides mediated therapies target the source of pathogenesis and have higher chance of success as compared to therapies that target downstream pathways. These are drugs for the treatment of central nervous system (CNS) disorders, as they have specific molecular targeting and extended pharmacological properties.

Market Analysis and Insights: Global CNS Specific Antisense Oligonucleotides Market
In 2021, the global CNS Specific Antisense Oligonucleotides market size will be US$ million and it is expected to reach US$ million by the end of 2027, with a CAGR of % during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global CNS Specific Antisense Oligonucleotides market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global CNS Specific Antisense Oligonucleotides market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global CNS Specific Antisense Oligonucleotides market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global CNS Specific Antisense Oligonucleotides market.

Global CNS Specific Antisense Oligonucleotides Scope and Market Size
CNS Specific Antisense Oligonucleotides market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global CNS Specific Antisense Oligonucleotides market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Polyneuropathy Treatment
Spinal Muscular Atrophy (SMA) Treatment
Huntington’s Disease Treatment

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Akcea Therapeutics, Inc.
Ionis Pharmaceuticals Inc.
Biogen Inc.
Sarepta Therapeutics
Wave Life Sciences Ltd.
Dynacure
ProQR Therapeutics N.V.
Stroke Therapeutic Inc.